Literature DB >> 12783609

Liver stem cells: prospects for treatment of inherited and acquired liver diseases.

Neil D Theise1.   

Abstract

It is now understood that there are three cell compartments which physiologically contribute to vertebrate liver parenchymal maintenance and regeneration after injury: mature liver cells (hepatocytes, cholangiocytes), intraorgan stem/progenitor cells (cells of the proximal biliary tree, periductal cells) and extraorgan stem cells (from the circulation and the bone marrow). All of these cell populations, as well as other, non-physiologic stem cells (e.g., mesenchymal stromal cells from the bone marrow, fetal hepatoblasts, embryonic stem [ES] cells), may be used therapeutically for treatment of inherited and acquired liver diseases. This article will summarise our current understanding of these various cell populations, and review possible approaches to their therapeutic use, including cell transplantation, bioartificial liver devices (BLDs), gene therapy and administration of exogenous factors to stimulate normal physiological responses to repair.

Entities:  

Mesh:

Year:  2003        PMID: 12783609     DOI: 10.1517/14712598.3.3.403

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  5 in total

1.  Current research in hepatic stem-cell function.

Authors:  Neil D Theise
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 2.  Adult stem cell plasticity: introduction to the first issue of stem cell reviews.

Authors:  Stewart Sell
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  Identification of expandable human hepatic progenitors which differentiate into mature hepatic cells in vivo.

Authors:  G Nowak; B-G Ericzon; S Nava; M Jaksch; M Westgren; S Sumitran-Holgersson
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 4.  Liver bioengineering: current status and future perspectives.

Authors:  Christopher Booth; Tom Soker; Pedro Baptista; Christina L Ross; Shay Soker; Umar Farooq; Robert J Stratta; Giuseppe Orlando
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

5.  3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway.

Authors:  Ning Wang; Xiajing Li; Zhiyong Zhong; Yaqi Qiu; Shoupei Liu; Haibin Wu; Xianglian Tang; Chuxin Chen; Yingjie Fu; Qicong Chen; Tingting Guo; Jinsong Li; Shuai Zhang; Mark A Zern; Keqiang Ma; Bailin Wang; Yimeng Ou; Weili Gu; Jie Cao; Honglin Chen; Yuyou Duan
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.